Skip to main content
. 2025 May 30;23:396. doi: 10.1186/s12951-025-03442-7

Table 2.

Inhalable nano-formulations under clinical application

Drug Nanocarrier Indication Status Ref
Amikacin Liposome Cystic Fibrosis patients with chronic pseudomonas aeruginosa infection Phase 3 NCT01316276
Amikacin Liposome Bronchiectasis Phase 2 NCT00775138
Salbutamol Sulphate Niosomes Pulmonary disease Phase 2 NCT03059017
Remdesivir (GS-5734) and NA-831 (NEUROSIVIR) Inhaled NP Severe acute respiratory syndrome Phase 1 NCT04480333
PRS-060 Lipocalin-1 Mild asthma Phase 1 NCT03574805